Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
166
-
Total 13F shares, excl. options
-
35.6M
-
Shares change
-
-546K
-
Total reported value, excl. options
-
$2.42B
-
Value change
-
-$81.3M
-
Put/Call ratio
-
1.8
-
Number of buys
-
102
-
Number of sells
-
-94
-
Price
-
$68.05
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q1 2018
231 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q1 2018.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 166 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.6M shares
of 49.6M outstanding shares and own 71.67% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (4.48M shares), VANGUARD GROUP INC (2.65M shares), ORBIMED ADVISORS LLC (2.64M shares), BlackRock Inc. (2.37M shares), Partner Fund Management, L.P. (2.03M shares), FMR LLC (1.59M shares), STATE STREET CORP (1.49M shares), D. E. Shaw & Co., Inc. (1.38M shares), Point72 Asset Management, L.P. (1.28M shares), and Redmile Group, LLC (1.1M shares).
This table shows the top 166 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.